Global Pulmonary Drug Delivery Systems Market Report to 2027 - Introduction of Smart Nebulizers Presents Opportunities

DUBLIN, Jan. 3, 2023 /PRNewswire/ -- The "Pulmonary Drug Delivery Systems: Technologies and Global Markets" report has been added to  ResearchAndMarkets.com's offering.

This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, R&D pipeline and blockbuster drugs.

In the report, the regulatory scenario of pulmonary drug delivery systems is discussed for each device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are also analyzed.

The report includes profiles of major companies in the market for pulmonary drug delivery systems, with overviews of their key product offerings and financials.

Companies Mentioned

• 3M
• Abbott Laboratories
• Astrazeneca
• Boehringer Ingelheim GmbH
• Cipla
• Dr. Reddy's Laboratories Ltd.
• GlaxoSmithKline plc
• Philips Respironics
• Lupin
• Mylan N.V.
• Merck Kgaa
• Novartis AG
• Omron Corp.
• Pfizer Inc.
• Pulmatrix Inc.
• Teva Pharmaceuticals Industries Ltd.

Report Includes

• 44 tables
• A brief overview and up-to-date analysis of the global markets for pulmonary drug delivery systems
• Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
• Estimation of the actual market size and revenue forecast for pulmonary drug delivery systems in USD value terms, and their corresponding market share analysis by type of drug delivery systems, application/disease area and region
• Highlights of the major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis; also, an industry-wide assessment of the key developments, novel products, recent approvals, R&D activities, pipeline products and blockbuster drugs
• In-depth information (facts and figures) concerning market drivers, opportunities and challenges, and other macroeconomic forces affecting the global pulmonary drug delivery systems market
• Holistic review of the international regulatory landscape for pulmonary drug delivery systems with emphasis on recently approved products as well as products under development or in different stages of clinical trials
• Updated information on key mergers and acquisition deals, agreements, collaborations and other impactful strategies adopted by key players in the global pulmonary drug delivery systems market
• Assessment of the recent patents published and granted on pulmonary drug delivery systems and related technologies
• Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues

Pulmonary drug delivery is an alternative to oral drug delivery. Pulmonary drug delivery is primarily advantageous for the treatment of respiratory diseases because it involves systemic administration via the alveolar region, which leads to fast absorption. The pulmonary drug delivery method depends on the development of simple, cost-effective and easy-to-use devices. These devices are designed to facilitate consistent drug delivery with increased lung penetration and multi-dosage facilities. Currently, manufacturers are concentrating on the development of small, portable devices that encourage higher patient compliance.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide according to the World Health Organization (WHO). In low and middle-income nations, COPD deaths in individuals under 70 years of age account for nearly 90% of all deaths in low- to middle-income countries (LMICs).

To stop the progression of symptoms and lessen flare-ups, early diagnosis and treatment are necessary, including support for quitting smoking. Key COPD risk factors include occupational exposure to dust, fumes and chemicals; indoor air pollution; and tobacco smoke. Long-term exposure to toxic gases and particles combined with individual factors, such as childhood lung development-influencing events and genetics, cause COPD. COPD results in persistent and advancing respiratory symptoms, such as coughing up phlegm and having trouble breathing.

The market for pulmonary drug delivery systems is growing rapidly due to the rising prevalence of respiratory disorders such as asthma, COPD and other chronic illnesses. Other factors driving its growth are the emergence of novel inhaler designs and increased use of non invasive drug delivery methods.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market Dynamics and Technology Background
3.1 Market Definition and Overview
3.1.1 Mechanism of Action
3.1.2 Advantages
3.1.3 Limitations/Challenges
3.2 Pulmonary Conditions and Therapies
3.2.1 Introduction to the Respiratory System
3.3 Market Drivers and Trends
3.3.1 Improved Patient Compliance and Ease of Use
3.3.2 Cost Pressures on Countries
3.3.3 Rising Incidence of Asthma
3.3.4 Causes
3.3.5 Reducing the Burden of Asthma
3.4 Market Restraints
3.4.1 Competition from Generics on the Rise
3.5 Market Opportunities
3.5.1 Introduction of Smart Nebulizers
3.6 Regulation and Legislation
3.6.1 U.S.

Chapter 4 Market Breakdown by Pulmonary Drug Delivery Systems
4.1 Overview of Inhalation Techniques
4.2 Dry Powder Inhalers (Dpis)
4.2.1 Overview
4.2.2 Marketed Products
4.3 Metered Dose Inhalers (Mdis)
4.3.1 Overview
4.3.2 Marketed Products
4.4 Nebulizers
4.4.1 Overview
4.4.2 Marketed Products Overview by Manufacturer

Chapter 5 Covid-19 Impact
5.1 Overview
5.2 Covid-19 Crisis
5.3 Impact on Market for Pulmonary Drug Delivery Systems
5.4 Current Outlook

Chapter 6 Pulmonary Drug Delivery Systems in Use
6.1 Therapeutic Agents Administered Via Inhalation
6.1.1 Steroids
6.1.2 Bronchodilators

Chapter 7 Market Breakdown by Disease Area

Chapter 8 Market Breakdown by Region

Chapter 9 Patent Analysis

Chapter 10 Company Profiles

Chapter 11 Appendix: Abbreviations

For more information about this report visit https://www.researchandmarkets.com/r/wb4tqc

Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
 
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
 
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets